1Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease(the 5th revised edition). Pediatr Int, 2005, 47(2):232-234.
2Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics, 2004,110( 17):2747-2771.
4Henter JI, Home A, Aric 6 M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 2007,48(2): 124-131.
5Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis.Arch Dis Child, 2011,96(7):688-693.
6Giordani L, Quaranta MG, Marchesi A, et al. ncreased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease. Clin Exp Immunol, 2011,163(3):346-353.
3Menasche G, Feldmann J, Fischer A, et al. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis [J]. Immunol Rev, 2005,203 : 165-179.
4Toitt I, Brostoff J, Male D. Immnulogy [M]. 6th ed. Harcourt Publishers Limited, 2001 : 235-258.
5Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophogocytic lympho- histiocytosis [J]. Science, 1999,286(5446) : 1957-1959.
7Zur Stadt U, Beutel K, Kolberg S, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STXII, and RAB27A [J]. Hum Mutat, 2006,27(1) :62-68.
8Feldmann J, Callebaut I, Raposo G, et al. Muncl3-4 is essential for eytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistioeytosis (FHL3) [J]. Cell,2003,115(4) :461-473.
9Yamamoto K, Ishii E, Sako M, et al. Identification of novel MUNC13-4 mutations in familial haemophagocytic lym-phohistiocytosis and functional analysis of MUNC13- 4-deficient cytotoxic T lymphocytes[J].J Med Genet, 2004,41 (10) :763-767.
10zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11[J]. Hum Mol Genet,2005,14(6) :827-834.
3Dogra S, Gehlot A, Suri D, et al. Incomplete Kawasaki Disease fol-lowed by Systemic Onset Juvenile Idiopathic Arthritis- The Diag- nostic Dilemma[J]. Indian J Pediatr,2013,80(9):783-785.
4Reed A, Haugen M, Pachman L M. Abnormalities in serum osteo- calcin values in children with chronic rheumatic diseases[J]. Jour- nal of Pediatrics,1990,116(4) : 574-580.
5Ayusawa M, Sonobe T, Uemura S, et aL Revision of diagnostic guidelines for Kawasaki disease(the 5th revised edition)[J].Pediatr Int,2005,47(2):232-234.
6Binstadt B A, Levine J C, Nigrovic P A, et al. Coronary artery dila- tion among patients presenting with systemic-onset juvenile idio- pathic arthritis[J].Pediatrics,2005,116:e89-e93.
7Dong S, Bout-Tabaku S, Texter K, et al. Diagnosis of Systemic-On- set Juvenile Idiopathic Arthritis after Treatment for Presumed Kawasaki Disease[J]. The Journal of pediateics Volume, 2015, 166 (5):1283-1288.
8Wang W, Gong F, Zhu W, et al. Macrophage activation syndrome in Kawasaki Disease: more common than we thought?[J]. Semin Arthritis Rheum, 2015,44(4):405-410.
9Minoia F, Davi S, Home A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating sys- temic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients[J]. Arthritis Rheumatol,2014,66(11):3160- 3169.
10Vastert S J, Kuis W, Grom A A. Systemic JIA:new developments in the understanding of the pathophysiology and therapy[J].Best Pract Res Clin Rheumatol,2009,23(5):655-664.
